One of the most promising drugs for the treatment of Alzheimer’s disease is a neurologist, director of the Neurological Diseases Clinic. AND ME. Professor Vladimir Parfenov of Sechenov University named the anti-amyloid drugs Lecanemab and Adukanumab.
“At the moment, the beta-amyloid hypothesis prevails. According to him, in the brain of a patient suffering from Alzheimer’s disease, beta-amyloid (this is a peptide – a short piece of protein) accumulates in the form of so-called amyloid plaques. Parfenov told socialbites.ca, beta-amyloid amyloid accumulates between neurons and has a toxic effect on them,” he explained.
The professor says that anti-amyloid drugs do work, although this hypothesis doesn’t explain much and there have been scientific papers from time to time that the beta-amyloid hypothesis isn’t true.
“Last June, the FDA (Food and Drug Administration, an agency of the U.S. Department of Health and Human Services) registered Aducanumab, the first drug for the treatment of early-stage Alzheimer’s disease. However, it has many side effects. In January of this year, clinical data on the efficacy of Lecanemab became available. Many drugs are still being tested, Parfyonov said.
For more information on whether early detection of Alzheimer’s disease is now possible, what tests allow it, why this diagnosis is so rare in Russia, and what needs to be done to slow the approaching dementia around the world. disease, cf. report “socialbites.ca”.